Cutaneous microcirculation is impaired in early autosomal dominant polycystic kidney disease

Nephron - Clinical Practice

Volumn 113, Issue 2, 2009, Pages

  Ramunni, Alfonso ^a   Brescia, Paola ^a   Quaranta, Domenico ^a   Bianco, Maria Stella ^a   Ranieri, Prudenza ^a   Dolce, Ernesta ^a   Coratelli, Pasquale ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Autosomal dominant polycystic kidney disease; Cutaneous blood flow; Endothelial dysfunction; Laser Doppler flowmetry; Lipoprotein (a)

Indexed keywords

AMLODIPINE; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; RAMIPRIL; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLOOD VESSEL REACTIVITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LASER DOPPLER FLOWMETRY; LIPOPROTEIN BLOOD LEVEL; MALE; MICROCIRCULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN BLOOD FLOW; SYSTEMIC CIRCULATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; FEMALE; HUMANS; MALE; MICROCIRCULATION; MICROVESSELS; PERIPHERAL VASCULAR DISEASES; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SKIN;

EID: 67650178575     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228537     Document Type: Article

References (37)

1. Kocaman O, Huseyin O, Yekeler E, et al: Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004; 43: 854-860.
2. Fick GM, Johnson AM, Hammond WS, Gabow PA: Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 5: 2048-2056.
3. Manjunath G, Tighiouart H, Ibrahim H, et al: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55. (Pubitemid 36044403)
4. Sarnak MJ, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease. Hypertension 2003; 42: 1050-1065.
5. Stam F, van Guldener C, Schalkwijk CG, et al: Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory acivity. Nephrol Dial Transplant 2003; 18: 892-898.
6. Ecder T, Schrier RW: Hypertension in autosomal- dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001; 12: 194-200.
7. Chapman AB, Johnson A, Gabow PA, Schrier RW: The rennin-angiotensin- aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323: 1091-1096. (Pubitemid 20370729)
8. Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW: Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997; 8: 1292-1297. (Pubitemid 27493634)
9. Bardaji A, Martinez-Vea A, Gutierrez C, Ridao C, Richart C, Oliver JA: Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998; 32: 970-975.
10. Gabow PA: Autosomal dominant polycystic kidney disease: more than a renal disease. Am J Kidney Dis 1990; 16: 403-413.
11. Wilson PD: Polycystic kidney disease. N Engl J Med 2004; 350: 151-164.
12. Griffin MD, Torres VE, Grande JP, Kumar R: Vascular expression of polycystin. J Am Soc Nephrol 1997; 8: 216-226.
13. Ibraghimov-Beskrovnaya O, Dackowski WR, Foggensteiner L, et al: Polycystin: in vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein. Proc Natl Acad Sci 1997; 94: 6397-6402.
14. Kim K, Drummond I, Ibraghimov-Beskrovnaya O, Klinger K, Arnaout A: Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 2000; 97: 1731-1736.
15. Wang D, Iversen J, Wilcox CS, Strandgaard S: Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal- dominant polycystic kidney disease. Kidney Int 2003; 64: 1381-1388.
16. Al-Nimri MA, Komers R, Oyama TT, Subramanya AR, Lindsley JN, Anderson S: Endothelial- derived vasoactive mediators in polycystic kidney disease. Kidney Int 2003; 63: 1776-1784.
17. Halcox JPG, Schenke WH, Zalos G, Mincemoyer R, et al: Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-658.
18. Gokce N, Keaney GF, Hunter LM, Watkins MT, Menzoian JO, Vita JA: Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105: 1567-1572.
19. Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction of adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
20. Al Suwaidi J, Hamasaki S, Higano ST, Nishimvra R, Holmes D, Lerman A: Longterm follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.
21. Blann AD: Assessment of endothelial dysfunction: focus on atherothrombotic disease. Pathophysiol Haemost Thromb 2003/ 2004; 33: 256-261.
22. Pasceri V, Willerosn JT, Yeh ET: Direct proinflammatory impact of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
23. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
24. Pearson TA: New tools for coronary risk assessment: what are their advantages and limitations? Circulation 2002; 105: 886-892.
25. Stewart J, Khoen A, Brouder D, et al: Noninvasive interrogation of microvasculature for signs of endothelial dysfunction in patients with chronic renal failure. Am J Physiol Heart Circ Physiol 2004; 287:H2687-H2696.
26. Kruger A, Stewart J, Sahityani R, O'Riordan E, et al: Laser Doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients: correlation with cardiovascular risk. Kidney Int 2006; 70: 157-164.
27. Kvandal P, Stefanovska A, Veber M, Kvermmo HD, Kirkvoen KA: Regulation of human cutaneous circulation evaluated by laser Doppler flowmetry, iontophoresis and spectral analysis: importance of nitric oxide and prostaglandins. Microvasc Res 2003; 65: 160-171.
28. Lindstedt IH, Edvinsson ML, Edvinsson L: Reduced responsiveness of cutaneous microcirculation in essential hypertension - a pilot study. Blood Press 2006; 15: 275-280.
29. Ramunni A, Saracino A, Esposito T, Saliani MT, Coratelli P: Renal vascular resistance and renin-angiotensin system in the pathogenesis of early hypertension in autosomal dominant polycystic kidney disease. Hypertens Res 2004; 27: 221-225.
30. Wang D, Iversen J, Strandgaard S: Endothelium- dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 1371-1376.
31. Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH: Human plasma lipoprotein (a): structural properties. J Biol Chem 1983; 258: 4582-4589.
32. Schlaich MP, John S, Langenfeld MR, Lackner KJ, Schmitz G, Schmieder RE: Does lipoprotein (a) impair endothelial function? J Am Coll Cardiol 1998; 31: 359-365.
33. Assmann G, Schulte H, von Eckaristein A: Hypertrigliceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-1184.
34. Nguyen TT, Ellefson RD, Hodge DO, Baileyk R, Kottke TE, Abu-Lebden HS: Predictive value of electrophoretically detective lipoprotein (a) for coronary heart disease and cerebrovascular disease in a communitybased cohort of 9936 men and women. Circulation 1997; 96: 1390-1397.
35. Marcovina SM, Koschisky ML: Lipoprotein (a) as a risk factor for coronary artery disease. Am J Cardiol 1998; 82: 57U-66U.
36. Yamazaki T, Katoh K, Nakanishi S, et al: Prediction of the severity of coronary artery disease by measurement of lipoprotein (a). Coron Artery Dis 1992; 3: 51-60.
37. Danish J, Collins R, Peto R: Lipoprotein (a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085.